Non-Tumorigenic Clones of the Dunning Prostate Tumor: Immunologic Analysis

1987 ◽  
Vol 137 (6) ◽  
Author(s):  
David M. Lubaroff ◽  
Timothy Volm
2006 ◽  
Vol 175 (4S) ◽  
pp. 310-310
Author(s):  
Nicholas J. Fitzsimons ◽  
Leon L. Sun ◽  
Thomas J. Polascik ◽  
Vladimir Mouraviev ◽  
Craig F. Donatucci ◽  
...  

2006 ◽  
Vol 175 (4S) ◽  
pp. 143-143
Author(s):  
Aubie Shaw ◽  
Jerry Gipp ◽  
Wade Bushman

1986 ◽  
Vol 56 (02) ◽  
pp. 133-136 ◽  
Author(s):  
Hamid Al-Mondhiry ◽  
Joseph Drago ◽  
Mary J Bartholomew

SummaryHypofibrinogenemia and disseminated intravascular coagulation are common events in patients with metastatic prostate carcinoma. This study tests the hypothesis that prostate tumor growth and metastasis is associated with sustained activation of fibrinolysis secondary to increased release of plasminogen activator. We implanted an androgen-insensitive prostate tumor into an inbred strain of rats and serially measured plasminogen, plasminogen activator, plasmin and fibrinogen. Control groups included animals without tumor and a group implanted with transitional cell bladder carcinoma, a locally infiltrating tumor not usually associated with hemostatic complications. Our results showed a significant and steady rise in plasma plasminogen activator, plasmin and fibrinogen levels in animals implanted with prostate cancer. This, however, is not specific for prostate tumor. Similar, perhaps more profound changes were noted in animals implanted with the transitional cell carcinoma.


2020 ◽  
Author(s):  
Lungwani Muungo

Engineered nanoparticles are widely used for delivery of drugs but frequently lack proof of safetyfor cancer patient's treatment. All-in-one covalent nanodrugs of the third generation have beensynthesized based on a poly(β-L-malic acid) (PMLA) platform, targeting human triple-negativebreast cancer (TNBC). They significantly inhibited tumor growth in nude mice by blockingsynthesis of epidermal growth factor receptor, and α4 and β1 chains of laminin-411, the tumorvascular wall protein and angiogenesis marker. PMLA and nanodrug biocompatibility and toxicityat low and high dosages were evaluated in vitro and in vivo. The dual-action nanodrug and singleactionprecursor nanoconjugates were assessed under in vitro conditions and in vivo with multipletreatment regimens (6 and 12 treatments). The monitoring of TNBC treatment in vivo withdifferent drugs included blood hematologic and immunologic analysis after multiple intravenousadministrations. The present study demonstrates that the dual-action nanoconju-gate is highlyeffective in preclinical TNBC treatment without side effects, supported by hematologic andimmunologic assays data. PMLA-based nanodrugs of the Polycefin™ family passed multipletoxicity and efficacy tests in vitro and in vivo on preclinical level and may prove to be optimizedand efficacious for the treatment of cancer patients in the future.


Sign in / Sign up

Export Citation Format

Share Document